Interpretation of WHO consolidated guidelines on tuberculosis, Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update

doi:10.19982/j.issn.1000-6621.20220523

Chinese Journal of Antituberculosis ›› 2023, Vol. 45 ›› Issue (4): 336-348.doi: 10.19982/j.issn.1000-6621.20220523

• Interpretation of Standards • Previous Articles Next Articles

Interpretation of WHO consolidated guidelines on tuberculosis, Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update

Fu Liang, Ren Tantan, Zhang Peize, Lu Shuihua()

Department of Pulmonary Medicine, National Clinical Research Center for Infectious Disease (Shenzhen), Shenzhen Third People’s Hospital, Southern University of Science and Technology, Shenzhen 518112, China

Received:2023-01-10 Online:2023-04-10 Published:2023-03-31
Contact: Lu Shuihua E-mail:lushuihua66@126.com
Supported by:
Special Fund for Science and Technology Innovation of Guangdong(2020B1111170014);Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties(SZGSP010);Shenzhen Natural Science Foundation(JCYJ20220530163212027);Shenzhen Scientific and Technological Foundation(JCYJ20180228162112889);Shenzhen Clinical Research Center for Tuberculosis(20210617141509001);Special Fund of Shenzhen Central-leading-local Scientific and Technological Foundation(LCYX20220620105200001);Summit Plan for Foshan High-Level Hospital Construction(FSSYYKF-2020001)

Abstract

Abstract:

World Health Organization (WHO) published the WHO consolidated guidelines on tuberculosis, Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update on February 15, 2022. The author introduced the main points of the updated guidelines, including the recommendations on the treatment of drug-resistant tuberculosis (focusing on a new short-term plan), management, patient care, and treatment monitoring, and discussed the feasibility of the guidelines in clinical practice and future research directions in China.

Key words: Drug resistance, multiple, bacterial, Tuberculosis, Drug therapy, combination, Program evaluation, Guidebooks

CLC Number:

Fu Liang, Ren Tantan, Zhang Peize, Lu Shuihua. Interpretation of WHO consolidated guidelines on tuberculosis, Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update[J]. Chinese Journal of Antituberculosis, 2023, 45(4): 336-348. doi: 10.19982/j.issn.1000-6621.20220523

[1]	World Health Organization. WHO consolidated guidelines on tuberculosis. Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization, 2022.
[2]	付亮, 高静韬, 邓国防, 等. 异烟肼耐药结核病治疗指南——WHO耐药结核病治疗补充指南. 国际呼吸杂志, 2018, 38(24): 1841-1845. doi:10.3760/cma.j.issn.1673-436X.2018.24.001. doi: 10.3760/cma.j.issn.1673-436X.2018.24.001
[3]	Lee A, Xie YL, Barry CE, et al. Current and future treatments for tuberculosis. BMJ, 2020, 368: m216. doi:10.1136/bmj.m216. doi: 10.1136/bmj.m216
[4]	李琦, 李亮. 耐多药或利福平耐药结核病长程化疗方案与短程化疗方案的利与弊. 中华结核和呼吸杂志, 2019, 42(5): 333-338. doi:10.3760/cma.j.issn.1001-0939.2019.05.005. doi: 10.3760/cma.j.issn.1001-0939.2019.05.005

[1]	Zhao Aihua, Du Weixin, Wang Guozhi, Xu Miao. Discussion on the nomenclature of recombinant Mycobacterium tuberculosis allergen skin test [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 333-335.
[2]	Teng Rencong, Li Tao, LI Yuhong, Yang Chenlu, Zhang Canyou, Zhao Yanlin, Zhang Hui. Analysis of registration records of elderly pulmonary tuberculosis patients aged 65 and above in China,2015—2021 [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 367-371.
[3]	Wu Tana, Li Yuhong, Liu Xiaoqiu. Study on the feasibility of active tuberculosis screening strategy for the elderly based on public health service [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 372-376.
[4]	Zhang Pei, Zhao Ahui, Gao Min, Zhen Xinan, Yao Yuxia, Jiang Jianguo, Sun Jianwei, Sun Dingyong. Epidemiological characteristics of MTB/HIV co-infection in Henan from 2016 to 2021 [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 377-382.
[5]	Mao Hongkai, Zhang Yan, Liang Zhichao, Xia Wenjun, Bao Liangliang, Mayisha·Daken , Wang Xiaomin, Cao Mingqin. Evaluation of implementation effect of pulmonary tuberculosis prevention and control strategy in southern Xinjiang based on synthetic control method [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 383-390.
[6]	Duan Yuheng, Zhang Lanyue, Dong Jing, Shi Yuting, Jia Hongyan, Li Zihui, Xing Aiying, Du Boping, Sun Qi, Pan Liping, Zhu Chuanzhi, Zhang Zongde. Effects of acetyltransferase fadA3 on acetylation of host protein and in vivo survival of Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 391-400.
[7]	Wang Yuanzhi, Long Meizhen, Liu Yiduo, Zhou Xiangmei. Application value of Mycobacterium bovis lipopolysaccharide in the serological diagnosis of tuberculosis in animals [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 401-405.
[8]	Zhu Yumei, Xia Zihan, Li Jinli, He Huishan, Wang Feng. Application value of multicolor melting curve analysis in detection of pre-extensive drug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 406-411.
[9]	Lai Min, Wu Guihui, Chen Hongde, Cheng Yao, Luo Haixia, He Kejing. Clinical characteristics and maternal and infant outcomes of 13 pregnant women with rifampicin resistant and multidrug resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 412-419.
[10]	Zhou Weidong, Zhang Zhengdong, Lin Mei, Li Tongxia. Progress in diagnosis and treatment of Mycobacterium avium-intracellular complex vertebral osteomyelitis [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 420-425.
[11]	Wang Wenjing, Sun Hong, Sun Zhaogang. Progress of innate immune mechanism activated by Mycobacterium tuberculosis DNA-mediated pattern recognition receptors [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 426-433.
[12]	Zou Yuanwu, Li Jing, Wang Biao, Wang Zhuo, Qu Shaoyi, Yuan Zhimin, Wu Qianhong. The diagnostic value of simultaneous amplification and testing for Mycobacterium tuberculosis technique on alveolar lavage fluid for diagnosing pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 434-436.
[13]	The Group of Osteoarticular Tuberculosis of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Expert consensus on the application of the concept of enhanced recovery after surgery in spinal tuberculosis surgery [J]. Chinese Journal of Antituberculosis, 2023, 45(3): 225-234.
[14]	Jia Fei, Cao Yanlin, Jiang Shiwen, Zhang Ke, Yi Min. Comparison and enlightenment of international legislation experience on tuberculosis control [J]. Chinese Journal of Antituberculosis, 2023, 45(3): 235-239.
[15]	Zhang Ke, Cao Yanlin, Jiang Shiwen, Chen Mingting, Jia Fei, Yi Min. Analysis of the current situation of local legislation on tuberculosis prevention and control in China [J]. Chinese Journal of Antituberculosis, 2023, 45(3): 240-243.

Interpretation of WHO consolidated guidelines on tuberculosis, Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 4

Related Articles 15

Recommended Articles

Metrics

Comments